These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 8665999)

  • 21. Simultaneous quantitation of d7-nefazodone, nefazodone, d7-hydroxynefazodone, hydroxynefazodone, m-chlorophenylpiperazine and triazole-dione in human plasma by liquid chromatographic-mass spectrometry.
    Yao M; Srinivas NR
    Biomed Chromatogr; 2000 Apr; 14(2):106-12. PubMed ID: 10694704
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic evaluation of co-administration of nefazodone and lithium in healthy subjects.
    Laroudie C; Salazar DE; Cosson JP; Cheuvart B; Istin B; Girault J; Ingrand I; Decourt JP
    Eur J Clin Pharmacol; 1999 Feb; 54(12):923-8. PubMed ID: 10192752
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical pharmacokinetics of nefazodone.
    Greene DS; Barbhaiya RH
    Clin Pharmacokinet; 1997 Oct; 33(4):260-75. PubMed ID: 9342502
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil.
    Muirhead GJ; Wilner K; Colburn W; Haug-Pihale G; Rouviex B
    Br J Clin Pharmacol; 2002; 53 Suppl 1(Suppl 1):21S-30S. PubMed ID: 11879256
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of the metabolites of the antidepressant drug nefazodone in human urine and plasma.
    Mayol RF; Cole CA; Luke GM; Colson KL; Kerns EH
    Drug Metab Dispos; 1994; 22(2):304-11. PubMed ID: 8013286
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Investigation of pharmacokinetic and pharmacodynamic interactions after coadministration of nefazodone and haloperidol.
    Barbhaiya RH; Shukla UA; Greene DS; Breul HP; Midha KK
    J Clin Psychopharmacol; 1996 Feb; 16(1):26-34. PubMed ID: 8834415
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-performance liquid chromatographic method for the determination of nefazodone and its metabolites in human plasma using laboratory robotics.
    Franc JE; Duncan GF; Farmen RH; Pittman KA
    J Chromatogr; 1991 Sep; 570(1):129-38. PubMed ID: 1797818
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sensitive liquid chromatographic-mass spectrometric assay for the simultaneous quantitation of nefazodone and its metabolites hydroxynefazodone m-chlorophenylpiperazine and triazole-dione in human plasma using single-ion monitoring.
    Yao M; Shah VR; Shyu WC; Srinivas NR
    J Chromatogr B Biomed Sci Appl; 1998 Oct; 718(1):77-85. PubMed ID: 9832363
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Determination of nefazodone and its metabolites in plasma by high-performance liquid chromatography with coulometric detection.
    Franklin M
    J Pharm Biomed Anal; 1993; 11(11-12):1109-13. PubMed ID: 8123721
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brain-to-blood partition and in vivo inhibition of 5-hydroxytryptamine reuptake and quipazine-mediated behaviour of nefazodone and its main active metabolites in rodents.
    Nacca A; Guiso G; Fracasso C; Cervo L; Caccia S
    Br J Pharmacol; 1998 Dec; 125(7):1617-23. PubMed ID: 9884092
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic and pharmacodynamic evaluation of warfarin and nefazodone coadministration in healthy subjects.
    Salazar DE; Dockens RC; Milbrath RL; Raymond RH; Fulmor IE; Chaikin PC; Uderman HD
    J Clin Pharmacol; 1995 Jul; 35(7):730-8. PubMed ID: 7560254
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: cytochromes mediating transformation, and P450-3A4 inhibitory actions.
    von Moltke LL; Greenblatt DJ; Granda BW; Grassi JM; Schmider J; Harmatz JS; Shader RI
    Psychopharmacology (Berl); 1999 Jul; 145(1):113-22. PubMed ID: 10445380
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-throughput quantitation of nefazodone and its metabolites in human plasma by high flow direct-injection LC-MS/MS.
    Mao Y; Huang MQ; Xia YQ; Jemal M
    J Pharm Biomed Anal; 2007 Apr; 43(5):1808-19. PubMed ID: 17236738
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of renal impairment on the pharmacokinetics of levomilnacipran following a single oral dose of levomilnacipran extended-release capsule in humans.
    Chen L; Greenberg WM; Brand-Schieber E; Wangsa J; Periclou A; Ghahramani P
    Drug Des Devel Ther; 2015; 9():3293-300. PubMed ID: 26150701
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of age, gender, and diurnal variation on the steady-state pharmacokinetics of BMS-181101, an antidepressant, in healthy subjects.
    Srinivas NR; Shyu WC; Gleason C; Schuster A; Greene DS; Barbhaiya RH
    Clin Pharmacol Ther; 1997 Oct; 62(4):408-16. PubMed ID: 9357392
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Carbamazepine-nefazodone interaction in healthy subjects.
    Laroudie C; Salazar DE; Cosson JP; Cheuvart B; Istin B; Girault J; Ingrand I; Decourt JP
    J Clin Psychopharmacol; 2000 Feb; 20(1):46-53. PubMed ID: 10653208
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of pharmacokinetic and pharmacodynamic drug interactions between nefazodone and digoxin in healthy male volunteers.
    Dockens RC; Greene DS; Barbhaiya RH
    J Clin Pharmacol; 1996 Feb; 36(2):160-7. PubMed ID: 8852392
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of nefazodone on the single-dose pharmacokinetics of phenytoin in healthy male subjects.
    Marino MR; Langenbacher KM; Hammett JL; Nichola P; Uderman HD
    J Clin Psychopharmacol; 1997 Feb; 17(1):27-33. PubMed ID: 9004054
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute and subchronic effects of nefazodone and imipramine on highway driving, cognitive functions, and daytime sleepiness in healthy adult and elderly subjects.
    van Laar MW; van Willigenburg AP; Volkerts ER
    J Clin Psychopharmacol; 1995 Feb; 15(1):30-40. PubMed ID: 7714226
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of various factors on steady state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine.
    Ishida M; Otani K; Kaneko S; Ohkubo T; Osanai T; Yasui N; Mihara K; Higuchi H; Sugawara K
    Int Clin Psychopharmacol; 1995 Sep; 10(3):143-6. PubMed ID: 8675966
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.